|
292 Companies |
|
489 Products |
|
489 Products |
|
199 Mechanisms of Action |
|
25 Trials |
|
7769 News |
|
| «12...1617181920212223242526...156157» |
- || Kenketsu Glovenin-I (normal human immunoglobulin IV) / Takeda
Trial completion, Trial initiation date: Phase III Clinical Trial of NPB-01 in Patients With Guillain-Barr (clinicaltrials.gov) - Apr 11, 2017
P3, N=22, Completed, Sponsor: Nihon Pharmaceutical Co., Ltd
Recruiting --> Completed | Initiation date: Apr 2014 --> Oct 2014
- | New trial: FLAIR-SEP: Improved Detection of Multiple Sclerosis Plaques in Inversion Recovery by Optimization of Sequence Parameters (clinicaltrials.gov) - Apr 11, 2017
P=N/A, N=27, Completed, Sponsor: Fondation Ophtalmologique Adolphe de Rothschild
- | Phase classification, Trial primary completion date, Immunomodulating: Helminth-induced Immunomodulation Therapy (HINT) in Relapsing-remitting Multiple Sclerosis (clinicaltrials.gov) - Apr 11, 2017
P1, N=16, Active, not recruiting, Sponsor: University of Wisconsin, Madison
Recruiting --> Completed | Initiation date: Apr 2014 --> Oct 2014 Phase classification: P=N/A --> P1 | Trial primary completion date: Mar 2017 --> Apr 2016
- | New trial: EJERCITALES: Exercise and Arterial Stiffness in Systemic Lupus Erythematosus (clinicaltrials.gov) - Apr 10, 2017
P=N/A, N=60, Not yet recruiting, Sponsor: Fundaci
- || Humira (adalimumab) / Eisai, AbbVie
Trial primary completion date, HEOR: AGIL: Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis (clinicaltrials.gov) - Apr 10, 2017
P=N/A, N=4500, Recruiting, Sponsor: AbbVie (prior sponsor, Abbott)
Phase classification: P=N/A --> P1 | Trial primary completion date: Mar 2017 --> Apr 2016 Trial primary completion date: May 2018 --> Aug 2017
- | Trial completion, Enrollment change: Online Health Survey of Patients With Vitiligo Vulgaris/ Online Survey of Pediatric Patients With Vitiligo (clinicaltrials.gov) - Apr 10, 2017
P=N/A, N=3258, Completed, Sponsor: St. Luke's-Roosevelt Hospital Center
Trial primary completion date: May 2018 --> Aug 2017 Recruiting --> Completed | N=1500 --> 3258
- | Trial completion: Young With Diabetes Type 1 - Test of an mHealth App (clinicaltrials.gov) - Apr 10, 2017
P=N/A, N=140, Completed, Sponsor: Nordsjaellands Hospital
Recruiting --> Completed | N=1500 --> 3258 Active, not recruiting --> Completed
- | Trial primary completion date: PLASMASEP: Plasma Exchanges in Multiple Sclerosis (MS) Relapses (clinicaltrials.gov) - Apr 7, 2017
P3, N=80, Recruiting, Sponsor: University Hospital, Bordeaux
Active, not recruiting --> Completed Trial primary completion date: Jan 2017 --> Dec 2017
- | Trial completion, Video: Examining the Effects of Video-game Exercise on Mobility and Brain Plasticity in Individuals With Multiple Sclerosis (clinicaltrials.gov) - Apr 7, 2017
P=N/A, N=30, Completed, Sponsor: Ohio State University
Trial primary completion date: Jan 2017 --> Dec 2017 Active, not recruiting --> Completed
- | Remicade (infliximab) / Merck (MSD), Mitsubishi Tanabe, J&J
Trial withdrawal: Topical Infliximab in Autoimmune Eyes With Keratoprosthesis (clinicaltrials.gov) - Apr 7, 2017
P1/2, N=0, Withdrawn, Sponsor: James Chodosh, MD, MPH
Active, not recruiting --> Completed Enrolling by invitation --> Withdrawn
- || Trial primary completion date: BICAFMS: Validation of Brief Computerized Cognitive Assessment in Multiple Sclerosis (BCCAMS) (clinicaltrials.gov) - Apr 6, 2017
P=N/A, N=470, Recruiting, Sponsor: University Hospital, Bordeaux
Enrolling by invitation --> Withdrawn Trial primary completion date: Aug 2017 --> Dec 2017
- | New trial, HEOR: LUPP: Pilot Study to Investigate Contemplative Intervention in Lupus Patients (clinicaltrials.gov) - Apr 6, 2017
P=N/A, N=44, Not yet recruiting, Sponsor: University of Virginia
- | New trial: DISGO: Disappearance of Graves' Orbitopathy (clinicaltrials.gov) - Apr 5, 2017
P=N/A, N=99, Completed, Sponsor: University of Pisa
- | New trial, HEOR: QUEST: QUality of Control and slEep in Children With diabeteS, Using New Technology (clinicaltrials.gov) - Apr 5, 2017
P=N/A, N=36, Recruiting, Sponsor: Centre Hospitalier du Luxembourg
- | Vyvgart (efgartigimod alfa-fcab) / argenx, Broteio
New P2 trial: A Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of ARGX-113 in Patients With ITP (clinicaltrials.gov) - Apr 5, 2017
P2, N=36, Recruiting, Sponsor: arGEN-X BVBA
- | Trial primary completion date: ELECTOR_I: Home Monitoring of Patients With Rheumatoid Arthritis - an eHealth Development Study (clinicaltrials.gov) - Apr 5, 2017
P=N/A, N=240, Recruiting, Sponsor: Henrik Gudbergsen
Trial primary completion date: Aug 2017 --> Dec 2017 Trial primary completion date: Sep 2016 --> Jun 2017
- | Humira (adalimumab) / AbbVie
Trial primary completion date: The Effect of Adalimumab Plus Methotrexate (MTX) Versus Placebo Plus MTX on Cartilage in (RA) Patients (clinicaltrials.gov) - Apr 5, 2017
P3, N=30, Recruiting, Sponsor: Heinrich-Heine University, Duesseldorf
Trial primary completion date: Sep 2016 --> Jun 2017 Trial primary completion date: Oct 2015 --> Jan 2018
- | H.P. Acthar Gel (repository corticotropin injection) / Mallinckrodt
Enrollment change, Trial withdrawal: Acthar on Proteinuria in IgA Nephropathy Patients (clinicaltrials.gov) - Apr 5, 2017
P4, N=0, Withdrawn, Sponsor: Baylor College of Medicine
Trial primary completion date: Oct 2015 --> Jan 2018 N=26 --> 0 | Recruiting --> Withdrawn
- New trial: The Artificial Pancreas in Very Young Children With T1D - Pilot (KidsAP01) (clinicaltrials.gov) - Apr 5, 2017
P=N/A, N=30, Not yet recruiting, Sponsor: University of Cambridge
- | Humalog pen (insulin lispro) / Eli Lilly
New trial: Environmental Effects Type 1 Diabetes Mellitus (clinicaltrials.gov) - Apr 5, 2017
P=N/A, N=10, Recruiting, Sponsor: University of Hull
- | Trial completion, Enrollment change: Virtual Peer-to-Peer (VP2P) Support Mentoring for Juvenile Idiopathic Arthritis (JIA): A Pilot RCT (clinicaltrials.gov) - Apr 4, 2017
P=N/A, N=30, Completed, Sponsor: The Hospital for Sick Children
N=26 --> 0 | Recruiting --> Withdrawn Active, not recruiting --> Completed | N=40 --> 30
- | Trial completion: An Internet-based Self-management Program for Adolescents With Arthritis (clinicaltrials.gov) - Apr 4, 2017
P=N/A, N=333, Completed, Sponsor: The Hospital for Sick Children
Active, not recruiting --> Completed | N=40 --> 30 Recruiting --> Completed
- | Trial completion: SOCOG-MS: Study of Social Cognition by Morphological and Functional Imaging in Multiple Sclerosis Patients (clinicaltrials.gov) - Apr 4, 2017
P=N/A, N=35, Completed, Sponsor: University Hospital, Bordeaux
Recruiting --> Completed Recruiting --> Completed
- | Trial completion, Trial primary completion date: DIMMISI: Efficacy Study of "Imaginative Distention", a Self Managed Tool to Cope With Fatigue,Insomnia and Stress in pw Insomnia and pw MS (clinicaltrials.gov) - Apr 4, 2017
P=N/A, N=144, Completed, Sponsor: Niguarda Hospital
Recruiting --> Completed Active, not recruiting --> Completed | Trial primary completion date: Oct 2016 --> Oct 2015
- | Campath (alemtuzumab) / Sanofi
Trial termination: Islet Cell Transplantation Alone and CD34+ Donor Bone Marrow Cell Infusion in Type 1 Diabetes Mellitus (clinicaltrials.gov) - Apr 4, 2017
P2, N=3, Terminated, Sponsor: University of Miami
Completed --> Terminated; We did not achieve a tolerogenic profile. Subjects withdrew from protocol and enrolled in other islet transplant trials.
- ||| Trial completion: ACCU-CHEK Connect Personal Diabetes Management Study (PDM CONNECT) (clinicaltrials.gov) - Apr 4, 2017
P=N/A, N=125, Completed, Sponsor: Hoffmann-La Roche
Subjects withdrew from protocol and enrolled in other islet transplant trials. Recruiting --> Completed
- ||| Enrollment open: Insulet Artificial Pancreas Evaluating Meal Performance and Moderate Exercise (IDE2) (clinicaltrials.gov) - Apr 4, 2017
P=N/A, N=60, Recruiting, Sponsor: Insulet Corporation
Recruiting --> Completed Not yet recruiting --> Recruiting
- Trial primary completion date: Exploratory Study to Assess Clinical Response to Gilenya® (Fingolimod) in Hispanics With RRMS (clinicaltrials.gov) - Mar 31, 2017
P=N/A, N=50, Active, not recruiting, Sponsor: University of Southern California
Not yet recruiting --> Recruiting Trial primary completion date: Apr 2014 --> Jul 2017
- | Trial completion, Enrollment change: Wahls Paleo Diet and Progressive Multiple Sclerosis (clinicaltrials.gov) - Mar 31, 2017
P=N/A, N=15, Completed, Sponsor: Terry L. Wahls
Trial primary completion date: Apr 2014 --> Jul 2017 Active, not recruiting --> Completed | N=45 --> 15
- |||| Biomarker, Trial completion, IO biomarker: Follow up Study of Patients on Fingolimod Who Were Enrolled in the Original Biobank Study (CFTY720DDE01) (clinicaltrials.gov) - Mar 31, 2017
P4, N=133, Completed, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed | N=45 --> 15 Recruiting --> Completed
- | New trial: Use of the Nine Holes Peg Test in Multiple Sclerosis: Participation of Elementary Neurological Components in the Functional Evaluation of Manual Dexterity (clinicaltrials.gov) - Mar 31, 2017
P=N/A, N=30, Recruiting, Sponsor: Brugmann University Hospital
- | Trial completion: Post-Radioiodine Graves' Management: The PRAGMA-Study (clinicaltrials.gov) - Mar 30, 2017
P=N/A, N=803, Completed, Sponsor: Newcastle-upon-Tyne Hospitals NHS Trust
Recruiting --> Completed Recruiting --> Completed
- | interferon alpha-2b Paradigm pump infusion system / Medtronic
Trial completion: Assess the Efficacy of the Low Glucose Suspend (LGS) Feature in the MiniMed Paradigm (clinicaltrials.gov) - Mar 30, 2017
P=N/A, N=50, Completed, Sponsor: Medtronic Diabetes
Recruiting --> Completed Withheld --> Completed
- | HDV insulin lispro (HDV-L) / Diasome
New P2 trial: Comparison of Hepatic Directed Vesicle (HDV)-Insulin Lispro Versus Insulin Lispro to Further Improve Glycemic Control (clinicaltrials.gov) - Mar 30, 2017
P2, N=46, Not yet recruiting, Sponsor: Diasome Pharmaceuticals
- | New trial, Video: Video Game-based Therapy for Arm Weakness In Progressive Multiple Sclerosis (clinicaltrials.gov) - Mar 29, 2017
P=N/A, N=0, Recruiting, Sponsor: Ohio State University
- | Enrollment closed, Trial primary completion date: Vestibular Rehabilitation for Persons With Multiple Sclerosis: Who Benefits the Most? (MSVR3trial) (clinicaltrials.gov) - Mar 29, 2017
P=N/A, N=88, Active, not recruiting, Sponsor: University of Colorado, Denver
Withheld --> Completed Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2016 --> Oct 2017
- | Trial completion, Phase classification, Trial primary completion date: CTSM: Effects of the Cross-Training in Patients With Multiple Sclerosis (clinicaltrials.gov) - Mar 29, 2017
P=N/A, N=45, Completed, Sponsor: Università degli Studi di Sassari
Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2016 --> Oct 2017 Recruiting --> Completed | Phase classification: P1/2 --> PN/A | Trial primary completion date: Apr 2016 --> Mar 2017
- | New P1 trial: Multiple Ascending Dose Study of MK-5160 in Participants With Type 1 and Type 2 Diabetes Mellitus (MK-5160-002) (clinicaltrials.gov) - Mar 29, 2017
P1, N=48, Not yet recruiting, Sponsor: Merck Sharp & Dohme Corp.
- || AZD9567 / AstraZeneca
Trial primary completion date: A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses of AZD9567. (clinicaltrials.gov) - Mar 28, 2017
P1, N=64, Recruiting, Sponsor: AstraZeneca
Recruiting --> Completed | Phase classification: P1/2 --> PN/A | Trial primary completion date: Apr 2016 --> Mar 2017 Trial primary completion date: Apr 2017 --> Aug 2017
- ||| leramistat (MBS2320) / Istesso, J&J
Trial completion: Safety and Tolerability Study of MBS2320 in Healthy Subjects and Subjects With Rheumatoid Arthritis (clinicaltrials.gov) - Mar 28, 2017
P1, N=105, Completed, Sponsor: Modern Biosciences plc
Trial primary completion date: Apr 2017 --> Aug 2017 Recruiting --> Completed
- | Antiferon (interferon alpha kinoid) / Neovacs
Trial completion: Safety of IFNa Kinoid in Systemic Lupus Erythematosus (clinicaltrials.gov) - Mar 27, 2017
P1/2, N=28, Completed, Sponsor: Neovacs
Recruiting --> Completed Active, not recruiting --> Completed
- ||| Betaseron (IFN-β-1b) / Bayer
Trial completion, HEOR: BetaSleep: Investigating the Relationship Between Sleep, Quality of Life,Other Disorders and Therapies in MS Patients on Betaferon (clinicaltrials.gov) - Mar 27, 2017
P=N/A, N=138, Completed, Sponsor: Bayer
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | hydroxychloroquine / Generic mfg.
Trial completion, Enrollment change: Effect of HCQ on AnxA5 Resistance Assay in Antiphospholipid (aPL) Positive Patients With and Without Systemic Lupus Erythematosus (SLE) (clinicaltrials.gov) - Mar 27, 2017
P=N/A, N=33, Completed, Sponsor: Hospital for Special Surgery, New York
Active, not recruiting --> Completed Active, not recruiting --> Completed | N=50 --> 33
- ||||| Plegridy (PEG-interferon β-1a) / Biogen
New P4 trial: VITALITY: Effects of Vitamin K on Redness Associated With Injection Site Reactions in Participants Treated With Plegridy (clinicaltrials.gov) - Mar 27, 2017
P4, N=60, Not yet recruiting, Sponsor: Biogen
- ||||||| AcellBia (rituximab biosimilar) / Biocad, Kocak Farma
Trial completion: BIORA: Study of Safety and Efficacy of BCD-020 Comparing to MabThera in Patients With Rheumatoid Arthritis (clinicaltrials.gov) - Mar 27, 2017
P3, N=181, Completed, Sponsor: Biocad
Active, not recruiting --> Completed | N=50 --> 33 Active, not recruiting --> Completed
- | Trial primary completion date: Gadobutrol Versus Gadopentetate Dimeglumine or Gadobenate Dimeglumine Before DCE-MRI in Diagnosing Patients With Multiple Sclerosis, Grade II-IV Glioma, or Brain Metastases (clinicaltrials.gov) - Mar 27, 2017
P=N/A, N=14, Terminated, Sponsor: University of Southern California
Active, not recruiting --> Completed Trial primary completion date: May 2014 --> Oct 2014
- | Trial completion: STigma and Its Impact on Glucose Control aMong Youth With diAbetes, a Canada-Wide Study (clinicaltrials.gov) - Mar 27, 2017
P=N/A, N=380, Completed, Sponsor: McGill University Health Center
Trial primary completion date: May 2014 --> Oct 2014 Recruiting --> Completed
- | New trial: Feasibility Evaluation of an Artificial Pancreas With Glucose Prediction Trust Index (clinicaltrials.gov) - Mar 27, 2017
P=N/A, N=20, Recruiting, Sponsor: William Sansum Diabetes Center
- ||| Gvoke HypoPen (glucagon auto-injectable rescue pen) / Xeris Biopharma
New P3 trial: Glucose Response of G-Pen (Glucagon Injection) in Pediatric T1D Patients (clinicaltrials.gov) - Mar 27, 2017
P3, N=24, Recruiting, Sponsor: Xeris Pharmaceuticals
- | Trial completion: Safety of RG2077 in Patients With Multiple Sclerosis (clinicaltrials.gov) - Mar 26, 2017
P1, N=20, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting --> Completed No longer recruiting --> Completed